Surfactant protein A, phosphatidylcholine, and surfactant inhibitors in epithelial lining fluid. Correlation with surface activity, severity of respiratory distress syndrome, and outcome in small premature infants
- PMID: 1741552
- DOI: 10.1164/ajrccm/144.6.1376
Surfactant protein A, phosphatidylcholine, and surfactant inhibitors in epithelial lining fluid. Correlation with surface activity, severity of respiratory distress syndrome, and outcome in small premature infants
Abstract
Although surfactant deficiency at birth is the major cause of respiratory distress syndrome (RDS), there is insufficient data on surfactant and surfactant inhibitors after birth. In the present study, a total of 345 airway specimens (AS) from 61 neonates of gestational age of 24 to 29 wk (54 with RDS) were analyzed for concentrations of phosphatidylcholine (PC), saturated PC (SPC), surfactant protein A (SP-A), nonsedimentable protein, and free amino acids in epithelial lining fluid (ELF). The relationship between surfactant indices, surface activity, and severity of RDS was studied. Treatment with human surfactant containing SP-A increased [PC]ELF and [SPC]ELF to levels found in infants without RDS. In placebo-treated infants similar concentrations were first reached between Days 4 and 7. Surfactant treatment increased the low SP-A/SPC ratio, although this ratio remained lower than that in exogenous surfactant. In RDS, the concentrations of free amino acids in ELF were 6 to 31 times higher than in infants without RDS. The nonsedimentable proteins of AS and cationic amino acids increased the minimum surface tension of SP-A-deficient surfactant from AS. Addition of SP-A improved the surface activity. According to multiple regression analysis, In [PC]ELF (p less than 0.0001), SPC/PC ratio (p less than 0.0001), In SP-A/SPC ratio (p less than 0.0002), and [protein]ELF (p less than 0.01) correlated with alveolar-arterial oxygen pressure gradient. Of the infants weighing less than 1,000 g, those who were going to die or develop bronchopulmonary dysplasia had a strikingly lower SP-A/SPC ratio during the first week (less than 25 ng/nmol) than those surviving without BPD.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
Surfactant protein A and saturated phosphatidylcholine in respiratory distress syndrome.Am J Respir Crit Care Med. 1994 Dec;150(6 Pt 1):1672-7. doi: 10.1164/ajrccm.150.6.7952631. Am J Respir Crit Care Med. 1994. PMID: 7952631
-
Prenatal dexamethasone and exogenous surfactant therapy: surface activity and surfactant components in airway specimens.Pediatr Res. 1995 Nov;38(5):676-84. doi: 10.1203/00006450-199511000-00008. Pediatr Res. 1995. PMID: 8552433 Clinical Trial.
-
A multicenter, randomized, controlled trial of lucinactant versus poractant alfa among very premature infants at high risk for respiratory distress syndrome.Pediatrics. 2005 Apr;115(4):1030-8. doi: 10.1542/peds.2004-2231. Pediatrics. 2005. PMID: 15805381 Clinical Trial.
-
Inherited disorders of neonatal lung diseases.Turk J Pediatr. 2004 Apr-Jun;46(2):105-14. Turk J Pediatr. 2004. PMID: 15214737 Review.
-
The fate of exogenous surfactant in neonates with respiratory distress syndrome.Clin Pharmacokinet. 1994 Mar;26(3):215-32. doi: 10.2165/00003088-199426030-00005. Clin Pharmacokinet. 1994. PMID: 8194284 Review.
Cited by
-
Dose-response comparisons of five lung surfactant factor (LSF) preparations in an animal model of adult respiratory distress syndrome (ARDS).Br J Pharmacol. 1995 Jun;115(3):451-8. doi: 10.1111/j.1476-5381.1995.tb16354.x. Br J Pharmacol. 1995. PMID: 7582456 Free PMC article.
-
Single nucleotide polymorphisms in surfactant protein A1 are not associated with a lack of responsiveness to antenatal steroid therapy in a pregnant sheep model.Physiol Rep. 2022 Oct;10(19):e15477. doi: 10.14814/phy2.15477. Physiol Rep. 2022. PMID: 36200269 Free PMC article.
-
Management Practices During Perinatal Respiratory Transition of Very Premature Infants.Front Pediatr. 2022 May 10;10:862038. doi: 10.3389/fped.2022.862038. eCollection 2022. Front Pediatr. 2022. PMID: 35620146 Free PMC article. Review.
-
Surfactant therapy for meconium aspiration syndrome: current status.Drugs. 2005;65(18):2569-91. doi: 10.2165/00003495-200565180-00003. Drugs. 2005. PMID: 16392874 Review.
-
Differential Regulation of Human Surfactant Protein A Genes, SFTPA1 and SFTPA2, and Their Corresponding Variants.Front Immunol. 2021 Nov 30;12:766719. doi: 10.3389/fimmu.2021.766719. eCollection 2021. Front Immunol. 2021. PMID: 34917085 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials